Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Diabetes Reviews
  4. Volume 21, Issue 9
  5. Article
Volume 21, Issue 9
  • ISSN: 1573-3998
  • E-ISSN: 1875-6417

Abstract

The discovery of antivascular endothelial growth factor medications has resulted in a substantial change in diabetic retinopathy treatment. The most common cause of diabetic retinopathy blindness is Diabetic Macular Edema. The pathophysiology of Diabetic Macular Edema is thought to include the well-known pro-angiogenic and pro-permeability factor vascular endothelial growth factor. Over the past decade, drugs that impede the functions of vascular endothelial growth factors have established themselves as a standard-of-care treatment for a range of ocular ailments and improved patients' clinical results with diabetic retinopathy and Diabetic Macular Edema, and their frequency has grown exponentially with the introduction of these agents Pegaptanib, Ranibizumab, and Aflibercept which are approved for ophthalmic indications, while Bevacizumab is used off-label. These medications delivered intravitreally have halted the vascular development of diabetic retinopathy. Various randomized trials have proven that antivascular endothelial growth factor medication is safe and effective in preserving vision. Following an extensive period of preclinical development aimed at enhancing and defining its biological impacts, these drugs were shown in clinical trials to be effective in treating diabetic retinopathy and other ophthalmic conditions. Data from various sources suggest that Pegaptanib, Ranibizumab, and Aflibercept are costly, while Bevacizumab is cost-effective, and in low and middle-income nations, it is thus a desirable therapy choice. However, issues with compounding, counterfeiting, and off-label usage restrict its availability in many nations. The pharmacology, pharmacokinetics, pharmacodynamics, adverse effects, and contraindications of antivascular endothelial growth factor agents are discussed, and the results of clinical trials evaluating their efficacy are summarized.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cdr/10.2174/0115733998294968240405091023
2024-04-16
2025-04-04

  • From This Site

    /content/journals/cdr/10.2174/0115733998294968240405091023
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. IDF Diabetes Atlas2021Available from: https://diabetesatlas.org/data/en/world/
  2. ZhangB. ZhouZ. ZhangB. WangD. Efficacy and safety of various treatments for proliferative diabetic retinopathy: A systematic review and network meta-analysis.Front. Pharmacol.20211270950110.3389/fphar.2021.70950134858166
     [Google Scholar]
  3. AielloL.P. GardnerT.W. KingG.L. BlankenshipG. CavalleranoJ.D. FerrisF.L.III KleinR. Diabetic retinopathy.Diabetes Care199821114315610.2337/diacare.21.1.1439538986
     [Google Scholar]
  4. GardnerT.W. AntonettiD.A. Novel potential mechanisms for diabetic macular edema: Leveraging new investigational approaches.Curr. Diab. Rep.20088426326910.1007/s11892‑008‑0047‑518631437
     [Google Scholar]
  5. CheungN. MitchellP. WongT.Y. Diabetic retinopathy.Lancet2010376973512413610.1016/S0140‑6736(09)62124‑320580421
     [Google Scholar]
  6. MuñozB WestSK RubinGS Causes of blindness and visual impairment in a population of older Americans: The Salisbury Eye Evaluation Study. Arch Ophthalmol2000118681982510.1001/archopht.118.6.819
     [Google Scholar]
  7. WeihLM VanNewkirkMR McCartyCA TaylorHR Age-specific causes of bilateral visual impairment.Arch Ophthalmol2000118226426910.1001/archopht.118.2.264
     [Google Scholar]
  8. FongD.S. AielloL. GardnerT.W. KingG.L. BlankenshipG. CavalleranoJ.D. FerrisF.L.III KleinR. American Diabetes Association Retinopathy in diabetes.Diabetes Care200427Suppl. 1s84s8710.2337/diacare.27.2007.S8414693935
     [Google Scholar]
  9. FriedmanDS O'ColmainBJ MuñozB Prevalence of age-related macular degeneration in the United States.Arch Ophthalmol200412245647210.1001/archopht.122.4.564
     [Google Scholar]
  10. JohnsonM.W. Etiology and treatment of macular edema.Am. J. Ophthalmol.200914711121.e110.1016/j.ajo.2008.07.02418789796
     [Google Scholar]
  11. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group.Arch Ophthalmol19851031217968062866759
     [Google Scholar]
  12. BrownD.M. NguyenQ.D. MarcusD.M. BoyerD.S. PatelS. FeinerL. SchlottmannP.G. RundleA.C. ZhangJ. RubioR.G. AdamisA.P. EhrlichJ.S. HopkinsJ.J. RIDE and RISE Research Group Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE.Ophthalmology2013120102013202210.1016/j.ophtha.2013.02.03423706949
     [Google Scholar]
  13. HahnP. AcquahK. CousinsS.W. LeeP.P. SloanF.A. Ten-year incidence of age-related macular degeneration according to diabetic retinopathy classification among medicare beneficiaries.Retina201333591191910.1097/IAE.0b013e318283124823407352
     [Google Scholar]
  14. SmiddyW.E. FlynnH.W.Jr Vitrectomy in the management of diabetic retinopathy.Surv. Ophthalmol.199943649150710.1016/S0039‑6257(99)00036‑310416792
     [Google Scholar]
  15. Dahl-JørgensenK. Brinchmann-HansenO. HanssenK.F. SandvikL. AagenaesO. Rapid tightening of blood glucose control leads to transient deterioration of retinopathy in insulin dependent diabetes mellitus: the Oslo study.BMJ1985290647181181510.1136/bmj.290.6471.8113919804
     [Google Scholar]
  16. NicholsonB.P. SchachatA.P. A review of clinical trials of anti-VEGF agents for diabetic retinopathy.Graefes Arch. Clin. Exp. Ophthalmol.2010248791593010.1007/s00417‑010‑1315‑z20174816
     [Google Scholar]
  17. QaumT. XuQ. JoussenA.M. ClemensM.W. QinW. MiyamotoK. HassessianH. WiegandS.J. RudgeJ. YancopoulosG.D. AdamisA.P. VEGF-initiated blood-retinal barrier breakdown in early diabetes.Invest. Ophthalmol. Vis. Sci.200142102408241311527957
     [Google Scholar]
  18. FunatsuH. YamashitaH. IkedaT. MimuraT. EguchiS. HoriS. Vitreous levels of interleukin-6 and vascular endothelial growth factor are related to diabetic macular edema.Ophthalmology200311091690169610.1016/S0161‑6420(03)00568‑213129863
     [Google Scholar]
  19. FunatsuH. YamashitaH. SakataK. NomaH. MimuraT. SuzukiM. EguchiS. HoriS. Vitreous levels of vascular endothelial growth factor and intercellular adhesion molecule 1 are related to diabetic macular edema.Ophthalmology2005112580681610.1016/j.ophtha.2004.11.04515878060
     [Google Scholar]
  20. TolentinoM.J. McleodD.S. TaomotoM. OtsujiT. AdamisA.P. LuttyG.A. Pathologic features of vascular endothelial growth factor-induced retinopathy in the nonhuman primate.Am. J. Ophthalmol.2002133337338510.1016/S0002‑9394(01)01381‑211860975
     [Google Scholar]
  21. BellC. LynamE. LandfairD.J. JanjicN. WilesM.E. Oligonucleotide NX1838 inhibits VEGF165-mediated cellular responses in vitro .In Vitro Cell. Dev. Biol. Anim.199935953354210.1007/s11626‑999‑0064‑y10548435
     [Google Scholar]
  22. TuerkC. GoldL. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase.Science1990249496850551010.1126/science.22001212200121
     [Google Scholar]
  23. RuckmanJ. GreenL.S. BeesonJ. WaughS. GilletteW.L. HenningerD.D. Claesson-WelshL. JanjićN. 2′-Fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF165). Inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain.J. Biol. Chem.199827332205562056710.1074/jbc.273.32.205569685413
     [Google Scholar]
  24. MorjariaR. ChongN.V. Pharmacokinetic evaluation of pegaptanib octasodium for the treatment of diabetic edema.Expert Opin. Drug Metab. Toxicol.20141081185119210.1517/17425255.2014.92254324856361
     [Google Scholar]
  25. BlickS.K.A. KeatingG.M. WagstaffA.J. Ranibizumab.Drugs20076781199120610.2165/00003495‑200767080‑0000717521219
     [Google Scholar]
  26. HicklinD.J. EllisL.M. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis.J. Clin. Oncol.20052351011102710.1200/JCO.2005.06.08115585754
     [Google Scholar]
  27. RosenLS Clinical experience with angiogenesis signaling inhibitors: focus on vascular endothelial growth factor (VEGF) blockers.Cancer Control200292 Suppl364410.1177/107327480200902S0511965229
     [Google Scholar]
  28. WangY. FeiD. VanderlaanM. SongA. Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro .Angiogenesis20047433534510.1007/s10456‑004‑8272‑215886877
     [Google Scholar]
  29. HolashJ. DavisS. PapadopoulosN. CrollS.D. HoL. RussellM. BolandP. LeidichR. HyltonD. BurovaE. IoffeE. HuangT. RadziejewskiC. BaileyK. FandlJ.P. DalyT. WiegandS.J. YancopoulosG.D. RudgeJ.S. VEGF-Trap: A VEGF blocker with potent antitumor effects.Proc. Natl. Acad. Sci. USA20029917113931139810.1073/pnas.17239829912177445
     [Google Scholar]
  30. DroletD.W. NelsonJ. TuckerC.E. ZackP.M. NixonK. BolinR. JudkinsM.B. FarmerJ.A. WolfJ.L. GillS.C. BendeleR.A. Pharmacokinetics and safety of an anti-vascular endothelial growth factor aptamer (NX1838) following injection into the vitreous humor of rhesus monkeys.Pharm. Res.200017121503151010.1023/A:100765710901211303960
     [Google Scholar]
  31. VinoresS.A. Technology evaluation: Pegaptanib, Eyetech/Pfizer.Curr. Opin. Mol. Ther.20035667367914755895
     [Google Scholar]
  32. KourlasH. SchillerD.S. Pegaptanib sodium for the treatment of neovascular age-related macular degeneration: A review.Clin. Ther.2006281364410.1016/j.clinthera.2006.01.00916490578
     [Google Scholar]
  33. ChapmanJ.A. BeckeyC. Pegaptanib: A novel approach to ocular neovascularization.Ann. Pharmacother.2006407-81322132610.1345/aph.1G60416849623
     [Google Scholar]
  34. Eyetech Study GroupPreclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration.Retina200222214315210.1097/00006982‑200204000‑0000211927845
     [Google Scholar]
  35. RxReasonerMACUGEN Solution for injectionAvailable from: https://www.rxreasoner.com/monographs/macugen/pharmacology (Accessed on: 2022 21 December).
  36. DoggrellS.A. Pegaptanib: The first antiangiogenic agent approved for neovascular macular degeneration.Expert Opin. Pharmacother.2005681421142310.1517/14656566.6.8.142116013991
     [Google Scholar]
  37. VinoresS.A. Pegaptanib in the treatment of wet, age-related macular degeneration.Int. J. Nanomedicine20061326326817717967
     [Google Scholar]
  38. AdamisA.P. ShimaD.T. The role of vascular endothelial growth factor in ocular health and disease.Retina200525211111810.1097/00006982‑200502000‑0000115689799
     [Google Scholar]
  39. FerraraN. DamicoL. ShamsN. LowmanH. KimR. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration.Retina200626885987010.1097/01.iae.0000242842.14624.e717031284
     [Google Scholar]
  40. GaudreaultJ. FeiD. RusitJ. SubocP. ShiuV. Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration.Invest. Ophthalmol. Vis. Sci.200546272673310.1167/iovs.04‑060115671306
     [Google Scholar]
  41. GaudreaultJ. FeiD. BeyerJ.C. RyanA. RangellL. ShiuV. DamicoL.A. Pharmacokinetics and retinal distribution of ranibizumab, a humanized antibody fragment directed against VEGF-A, following intravitreal administration in rabbits.Retina20072791260126610.1097/IAE.0b013e318134eecd18046235
     [Google Scholar]
  42. BakriS.J. SnyderM.R. ReidJ.M. PulidoJ.S. EzzatM.K. SinghR.J. Pharmacokinetics of intravitreal ranibizumab (Lucentis).Ophthalmology2007114122179218210.1016/j.ophtha.2007.09.01218054637
     [Google Scholar]
  43. NiwaY. KakinokiM. SawadaT. WangX. OhjiM. Ranibizumab and Aflibercept: intraocular pharmacokinetics and their effects on aqueous VEGF level in vitrectomized and nonvitrectomized macaque eyes.Invest. Ophthalmol. Vis. Sci.201556116501650510.1167/iovs.15‑1727926447985
     [Google Scholar]
  44. LoweJ. AraujoJ. YangJ. ReichM. OldendorpA. ShiuV. QuarmbyV. LowmanH. LienS. GaudreaultJ. MaiaM. Ranibizumab inhibits multiple forms of biologically active vascular endothelial growth factor in vitro and in vivo.Exp. Eye Res.200785442543010.1016/j.exer.2007.05.00817714704
     [Google Scholar]
  45. LinY.S. NguyenC. MendozaJ.L. EscandonE. FeiD. MengY.G. ModiN.B. Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor.J. Pharmacol. Exp. Ther.199928813713789862791
     [Google Scholar]
  46. GordonM.S. MargolinK. TalpazM. SledgeG.W.Jr HolmgrenE. BenjaminR. StalterS. ShakS. AdelmanD.C. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer.J. Clin. Oncol.200119384385010.1200/JCO.2001.19.3.84311157038
     [Google Scholar]
  47. ScheinbergD.A. SgourosG. JunghansR.P. Antibody-based immunotherapies for cancer.3rd ed ChabnerB.A. LongoD.L. PhiladelphiaLippincott Williams and Wilkins2001
     [Google Scholar]
  48. ZondorS.D. MedinaP.J. Bevacizumab: An angiogenesis inhibitor with efficacy in colorectal and other malignancies.Ann. Pharmacother.2004387-81258126410.1345/aph.1D47015187215
     [Google Scholar]
  49. StewartM.W. Predicted biologic activity of intravitreal bevacizumab.Retina20072791196120010.1097/IAE.0b013e318158ea2818046224
     [Google Scholar]
  50. BenayounY. AdenisJ.P. CasseG. ForteR. RobertP.Y. Effects of subconjunctival bevacizumab on corneal neovascularization: Results of a prospective study.Cornea201231893794410.1097/ICO.0b013e31823f8d7122357391
     [Google Scholar]
  51. BockF. OnderkaJ. DietrichT. BachmannB. KruseF.E. PaschkeM. ZahnG. CursiefenC. Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis.Invest. Ophthalmol. Vis. Sci.20074862545255210.1167/iovs.06‑057017525183
     [Google Scholar]
  52. DastjerdiM.H. SabanD.R. OkanoboA. NallasamyN. SadraiZ. ChauhanS.K. HajrasoulihaA.R. DanaR. Effects of topical and subconjunctival bevacizumab in high-risk corneal transplant survival.Invest. Ophthalmol. Vis. Sci.20105152411241710.1167/iovs.09‑374519892863
     [Google Scholar]
  53. FernandoN. HurwitzH. Inhibition of vascular endothelial growth factor in the treatment of colorectal cancer.Semin. Oncol.2003303Suppl. 6395010.1016/S0093‑7754(03)70024‑412802794
     [Google Scholar]
  54. KimK.J. LiB. WinerJ. ArmaniniM. GillettN. PhillipsH.S. FerraraN. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo.Nature1993362642384184410.1038/362841a07683111
     [Google Scholar]
  55. WarrenR.S. YuanH. MatliM.R. GillettN.A. FerraraN. Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis.J. Clin. Invest.19959541789179710.1172/JCI1178577535799
     [Google Scholar]
  56. BorgströmP. GoldD.P. HillanK.J. FerraraN. Importance of VEGF for breast cancer angiogenesis in vivo: Implications from intravital microscopy of combination treatments with an anti-VEGF neutralizing monoclonal antibody and doxorubicin.Anticancer Res.1999195B4203421410628376
     [Google Scholar]
  57. CursiefenC. ChenL. BorgesL.P. JacksonD. CaoJ. RadziejewskiC. D’AmoreP.A. DanaM.R. WiegandS.J. StreileinJ.W. VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment.J. Clin. Invest.200411371040105010.1172/JCI2046515057311
     [Google Scholar]
  58. OliveiraH.B. SakimotoT. JavierJ.A.D. AzarD.T. WiegandS.J. JainS. ChangJ.H. VEGF Trap(R1R2) suppresses experimental corneal angiogenesis.Eur. J. Ophthalmol.2010201485410.1177/11206721100200010619882518
     [Google Scholar]
  59. ChristoforidisJ.B. WilliamsM.M. KothandaramanS. KumarK. EpitropoulosF.J. KnoppM.V. Pharmacokinetic properties of intravitreal I-124-aflibercept in a rabbit model using PET/CT.Curr. Eye Res.201237121171117410.3109/02713683.2012.72752122991959
     [Google Scholar]
  60. WellsJ.A. GlassmanA.R. AyalaA.R. JampolL.M. AielloL.P. AntoszykA.N. Arnold-BushB. BakerC.W. BresslerN.M. BrowningD.J. ElmanM.J. FerrisF.L. FriedmanS.M. MeliaM. PieramiciD.J. SunJ.K. BeckR.W. Diabetic Retinopathy Clinical Research Network Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema.N. Engl. J. Med.2015372131193120310.1056/NEJMoa141426425692915
     [Google Scholar]
  61. KaiserP.K. KodjikianL. KorobelnikJ.F. WinklerJ. TorriA. ZeitzO. VittiR. AhlersC. ZimmermannT. DicioccioA.T. HöchelJ. Systemic pharmacokinetic/pharmacodynamic analysis of intravitreal aflibercept injection in patients with retinal diseases.BMJ Open Ophthalmol.201941e00018510.1136/bmjophth‑2018‑00018530997397
     [Google Scholar]
  62. MauriceD.M. MishimaS. Ocular pharmacokinetics.Pharmacology of the Eye. SearsM.L. Berlin, HeidelbergSpringer Berlin Heidelberg19841911610.1007/978‑3‑642‑69222‑2_2
     [Google Scholar]
  63. CaoJ. ZhaoL. LiY. LiuY. XiaoW. SongY. LuoL. HuangD. YancopoulosG.D. WiegandS.J. WenR. A subretinal matrigel rat choroidal neovascularization (CNV) model and inhibition of CNV and associated inflammation and fibrosis by VEGF trap.Invest. Ophthalmol. Vis. Sci.201051116009601710.1167/iovs.09‑495620538989
     [Google Scholar]
  64. NorkTM DubielzigRR ChristianBJ Prevention of experimental choroidal neovascularization and resolution of active lesions by VEGF trap in nonhuman primates.Arch Ophthalmol2011129810425210.1001/archophthalmol.2011.21021825187
     [Google Scholar]
  65. KeatingG.M. Aflibercept: A review of its use in diabetic macular oedema.Drugs201575101153116010.1007/s40265‑015‑0421‑y26056030
     [Google Scholar]
  66. YangL.P.H. McKeageK. Intravitreal aflibercept (Eylea(®)): A review of its use in patients with macular oedema secondary to central retinal vein occlusion.Drugs Aging201431539540410.1007/s40266‑014‑0176‑224740170
     [Google Scholar]
  67. FramptonJ.E. Aflibercept for intravitreal injection: In neovascular age-related macular degeneration.Drugs Aging2012291083984610.1007/s40266‑012‑0015‑223038609
     [Google Scholar]
  68. KimE.S. SerurA. HuangJ. ManleyC.A. McCruddenK.W. FrischerJ.S. SofferS.Z. RingL. NewT. ZabskiS. RudgeJ.S. HolashJ. YancopoulosG.D. KandelJ.J. YamashiroD.J. Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma.Proc. Natl. Acad. Sci. USA20029917113991140410.1073/pnas.17239839912177446
     [Google Scholar]
  69. XuD. KaiserP.K. Intravitreal aflibercept for neovascular age-related macular degeneration.Immunotherapy20135212113010.2217/imt.12.15823413903
     [Google Scholar]
  70. PapadopoulosN. MartinJ. RuanQ. RafiqueA. RosconiM.P. ShiE. PylesE.A. YancopoulosG.D. StahlN. WiegandS.J. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab.Angiogenesis201215217118510.1007/s10456‑011‑9249‑622302382
     [Google Scholar]
  71. StewartM.W. Aflibercept ophthalmic solution: Drug development and clinical uses.Clin. Investig.20133111045105610.4155/cli.13.94
     [Google Scholar]
  72. StewartM.W. Aflibercept (VEGF Trap-Eye) for the treatment of exudative age-related macular degeneration.Expert Rev. Clin. Pharmacol.20136210311310.1586/ecp.12.8123473589
     [Google Scholar]
  73. StewartM.W. RosenfeldP.J. Predicted biological activity of intravitreal VEGF Trap.Br. J. Ophthalmol.200892566766810.1136/bjo.2007.13487418356264
     [Google Scholar]
  74. ZhouB. WangB. Pegaptanib for the treatment of age-related macular degeneration.Exp. Eye Res.200683361561910.1016/j.exer.2006.02.01016678158
     [Google Scholar]
  75. Eyetech Study GroupAnti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration.Ophthalmology2003110597998610.1016/S0161‑6420(03)00085‑X12750101
     [Google Scholar]
  76. CunninghamE.T.Jr AdamisA.P. AltaweelM. AielloL.P. BresslerN.M. D’AmicoD.J. GoldbaumM. GuyerD.R. KatzB. PatelM. SchwartzS.D. Macugen Diabetic Retinopathy Study Group A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema.Ophthalmology2005112101747175710.1016/j.ophtha.2005.06.00716154196
     [Google Scholar]
  77. SultanM.B. ZhouD. LoftusJ. DombiT. IceK.S. Macugen 1013 Study Group A phase 2/3, multicenter, randomized, double-masked, 2-year trial of pegaptanib sodium for the treatment of diabetic macular edema.Ophthalmology201111861107111810.1016/j.ophtha.2011.02.04521529957
     [Google Scholar]
  78. GragoudasE.S. AdamisA.P. CunninghamE.T.Jr FeinsodM. GuyerD.R. VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group Pegaptanib for neovascular age-related macular degeneration.N. Engl. J. Med.2004351272805281610.1056/NEJMoa04276015625332
     [Google Scholar]
  79. JacksonT.L. AntcliffR.J. HillenkampJ. MarshallJ. Human retinal molecular weight exclusion limit and estimate of species variation.Invest. Ophthalmol. Vis. Sci.20034452141214610.1167/iovs.02‑102712714654
     [Google Scholar]
  80. MordentiJ. CuthbertsonR.A. FerraraN. ThomsenK. BerleauL. LickoV. AllenP.C. ValverdeC.R. MengY.G. FeiD.T.W. FourreK.M. RyanA.M. Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration.Toxicol. Pathol.199927553654410.1177/01926233990270050710528633
     [Google Scholar]
  81. ChannaR. SophieR. KhwajaA.A. DoD.V. HafizG. NguyenQ.D. CampochiaroP.A. READ-2 Study Group Factors affecting visual outcomes in patients with diabetic macular edema treated with ranibizumab.Eye201428326927810.1038/eye.2013.24524263379
     [Google Scholar]
  82. NguyenQ.D. ShahS.M. KhwajaA.A. ChannaR. HatefE. DoD.V. BoyerD. HeierJ.S. AbrahamP. ThachA.B. LitE.S. FosterB.S. KrugerE. DugelP. ChangT. DasA. CiullaT.A. PollackJ.S. LimJ.I. EliotD. CampochiaroP.A. READ-2 Study Group Two-year outcomes of the ranibizumab for edema of the mAcula in diabetes (READ-2) study.Ophthalmology2010117112146215110.1016/j.ophtha.2010.08.01620855114
     [Google Scholar]
  83. NguyenQ.D. ShahS.M. HeierJ.S. DoD.V. LimJ. BoyerD. AbrahamP. CampochiaroP.A. READ-2 Study Group Primary end point (six months) results of the Ranibizumab for Edema of the mAcula in Diabetes (READ-2) study.Ophthalmology20091161121752181.e110.1016/j.ophtha.2009.04.02319700194
     [Google Scholar]
  84. DoD.V. NguyenQ.D. KhwajaA.A. ChannaR. SepahY.J. SophieR. HafizG. CampochiaroP.A. READ-2 Study Group Ranibizumab for edema of the macula in diabetes study: 3-year outcomes and the need for prolonged frequent treatment.JAMA Ophthalmol.2013131213914510.1001/2013.jamaophthalmol.9123544200
     [Google Scholar]
  85. MassinP. BandelloF. GarwegJ.G. HansenL.L. HardingS.P. LarsenM. MitchellP. SharpD. Wolf-SchnurrbuschU.E.K. GekkievaM. WeichselbergerA. WolfS. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study.Diabetes Care201033112399240510.2337/dc10‑049320980427
     [Google Scholar]
  86. NguyenQ.D. BrownD.M. MarcusD.M. BoyerD.S. PatelS. FeinerL. GibsonA. SyJ. RundleA.C. HopkinsJ.J. RubioR.G. EhrlichJ.S. RISE and RIDE Research Group Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE.Ophthalmology2012119478980110.1016/j.ophtha.2011.12.03922330964
     [Google Scholar]
  87. BrechnerR.J. RosenfeldP.J. BabishJ.D. CaplanS. Pharmacotherapy for neovascular age-related macular degeneration: an analysis of the 100% 2008 medicare fee-for-service part B claims file.Am. J. Ophthalmol.20111515887895.e110.1016/j.ajo.2010.11.01721310390
     [Google Scholar]
  88. ÖzkirişA. Intravitreal bevacizumab (Avastin) for primary treatment of diabetic macular oedema.Eye (Lond.)200923361662010.1038/eye.2008.4018437176
     [Google Scholar]
  89. NguyenQD ShahSM HafizG A phase I trial of an IV-administered vascular endothelial growth factor trap for treatment in patients with choroidal neovascularization due to age-related macular degeneration.Ophthalmology200611391522.e1e14
     [Google Scholar]
  90. RosenfeldP.J. BrownD.M. HeierJ.S. BoyerD.S. KaiserP.K. ChungC.Y. KimR.Y. MARINA Study Group Ranibizumab for neovascular age-related macular degeneration.N. Engl. J. Med.2006355141419143110.1056/NEJMoa05448117021318
     [Google Scholar]
  91. DoD.V. NguyenQ.D. ShahS.M. BrowningD.J. HallerJ.A. ChuK. YangK. CedarbaumJ.M. VittiR.L. IngermanA. CampochiaroP.A. An exploratory study of the safety, tolerability and bioactivity of a single intravitreal injection of vascular endothelial growth factor Trap-Eye in patients with diabetic macular oedema.Br. J. Ophthalmol.200993214414910.1136/bjo.2008.13827119174400
     [Google Scholar]
  92. DoD.V. NguyenQ.D. BoyerD. Schmidt-ErfurthU. BrownD.M. VittiR. BerlinerA.J. GaoB. ZeitzO. RuckertR. SchmelterT. SandbrinkR. HeierJ.S. da Vinci Study Group One-year outcomes of the da Vinci Study of VEGF Trap-Eye in eyes with diabetic macular edema.Ophthalmology201211981658166510.1016/j.ophtha.2012.02.01022537617
     [Google Scholar]
  93. DoD.V. Schmidt-ErfurthU. GonzalezV.H. GordonC.M. TolentinoM. BerlinerA.J. VittiR. RückertR. SandbrinkR. SteinD. YangK. BeckmannK. HeierJ.S. The DA VINCI Study: phase 2 primary results of VEGF Trap-Eye in patients with diabetic macular edema.Ophthalmology201111891819182610.1016/j.ophtha.2011.02.01821546089
     [Google Scholar]
  94. KorobelnikJ.F. DoD.V. Schmidt-ErfurthU. BoyerD.S. HolzF.G. HeierJ.S. MidenaE. KaiserP.K. TerasakiH. MarcusD.M. NguyenQ.D. JaffeG.J. SlakterJ.S. SimaderC. SooY. SchmelterT. YancopoulosG.D. StahlN. VittiR. BerlinerA.J. ZeitzO. MetzigC. BrownD.M. Intravitreal aflibercept for diabetic macular edema.Ophthalmology2014121112247225410.1016/j.ophtha.2014.05.00625012934
     [Google Scholar]
  95. HeierJ.S. BrownD.M. ChongV. KorobelnikJ.F. KaiserP.K. NguyenQ.D. KirchhofB. HoA. OguraY. YancopoulosG.D. StahlN. VittiR. BerlinerA.J. SooY. AnderesiM. GroetzbachG. SommerauerB. SandbrinkR. SimaderC. Schmidt-ErfurthU. VIEW 1 and VIEW 2 Study Groups Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration.Ophthalmology2012119122537254810.1016/j.ophtha.2012.09.00623084240
     [Google Scholar]
  96. BrownD.M. Schmidt-ErfurthU. DoD.V. HolzF.G. BoyerD.S. MidenaE. HeierJ.S. TerasakiH. KaiserP.K. MarcusD.M. NguyenQ.D. JaffeG.J. SlakterJ.S. SimaderC. SooY. SchmelterT. YancopoulosG.D. StahlN. VittiR. BerlinerA.J. ZeitzO. MetzigC. KorobelnikJ.F. Intravitreal aflibercept for diabetic macular edema.Ophthalmology2015122102044205210.1016/j.ophtha.2015.06.01726198808
     [Google Scholar]
  97. HeierJ.S. KorobelnikJ.F. BrownD.M. Schmidt-ErfurthU. DoD.V. MidenaE. BoyerD.S. TerasakiH. KaiserP.K. MarcusD.M. NguyenQ.D. JaffeG.J. SlakterJ.S. SimaderC. SooY. SchmelterT. VittiR. BerlinerA.J. ZeitzO. MetzigC. HolzF.G. Intravitreal aflibercept for diabetic macular edema.Ophthalmology2016123112376238510.1016/j.ophtha.2016.07.03227651226
     [Google Scholar]
  98. HurleySF MatthewsJP GuymerRH Cost-effectiveness of ranibizumab for neovascular age-related macular degeneration.Cost Eff Resour Alloc200861210.1186/1478‑7547‑6‑12
     [Google Scholar]
  99. AkiyodeO Dunkelly-AllenN. Ranibizumab: A review of its use in the treatment of diabetic retinopathy in patients with diabetic macular edema.J Pharm Technol2016321222810.1177/8755122515599552
     [Google Scholar]
  100. Bayer OpthalmologyEyles dosing.Available from: https://ophthalmology.bayer.com/eylea/dosing/dme
  101. Bayer Pharma AG. Eylea 40 mg/ml solution for injection in prefilled syringe: EU summary of product characteristics.Available from: https://www.ema.europa.eu/en/documents/product-information/eylea-epar-product-information_en.pdf
  102. RxList. MACUGEN.Available from: https://www.rxlist.com/macugen-drug.htm
  103. RxList. LUCENTIS.Available from: https://www.rxlist.com/lucentis-drug.htm
  104. Regeneron Pharmaceuticals Inc. EYLEA® (AFLIBERCEPT) injection receIVES EU approval for the treatment of DIABETIC MACULAR EDEMA (DME).Available from: https://investor.regeneron.com/news-releases/news-release-details/eylear-aflibercept-injection-receives-eu-approval-treatment/
  105. Regeneron Pharmaceuticals Inc. EYLEA® (AFLIBERCEPT) injection receives FDA approval for the treatment of DIABETIC MACULAR EDEMA (DME)2014Available from: https://newsroom.regeneron.com/news-releases/news-release-details/eylear-aflibercept-injection-receives-fda-approval-treatment (Accessed on: 2023 May 15).
  106. RxList. EYLEA.Available from: https://www.rxlist.com/eylea-drug.htm
  107. ApteR.S. ModiM. MasonsonH. PatelM. WhitfieldL. AdamisA.P. Macugen AMD Study Group Pegaptanib 1-year systemic safety results from a safety-pharmacokinetic trial in patients with neovascular age-related macular degeneration.Ophthalmology2007114917021712.e210.1016/j.ophtha.2007.02.02117509689
     [Google Scholar]
  108. Schmidt-ErfurthU. LangG.E. HolzF.G. SchlingemannR.O. LanzettaP. MassinP. GerstnerO. BouazzaA.S. ShenH. OsborneA. MitchellP. RESTORE Extension Study Group Three-year outcomes of individualized ranibizumab treatment in patients with diabetic macular edema: the RESTORE extension study.Ophthalmology201412151045105310.1016/j.ophtha.2013.11.04124491642
     [Google Scholar]
  109. NgE. NishijimaK. RobinsonG.S. AdamisA.P. ShimaD.T. VEGF has both direct and indirect neuroprotective effects in ischemic retina.Invest. Ophthalmol. Vis. Sci.200647134829
     [Google Scholar]
  110. MasonJ.O.III FrederickP.A. NeimkinM.G. WhiteM.F.Jr FeistR.M. ThomleyM.L. AlbertM.A.Jr Incidence of hemorrhagic complications after intravitreal bevacizumab (avastin) or ranibizumab (lucentis) injections on systemically anticoagulated patients.Retina20103091386138910.1097/IAE.0b013e3181e0973920924260
     [Google Scholar]
  111. BresslerS.B. AlmukhtarT. BhoradeA. BresslerN.M. GlassmanA.R. HuangS.S. JampolL.M. KimJ.E. MeliaM. Diabetic Retinopathy Clinical Research Network Investigators Repeated intravitreous ranibizumab injections for diabetic macular edema and the risk of sustained elevation of intraocular pressure or the need for ocular hypotensive treatment.JAMA Ophthalmol.2015133558959710.1001/jamaophthalmol.2015.18625719991
     [Google Scholar]
  112. WangW. ZhangX. Systemic adverse events after intravitreal bevacizumab versus ranibizumab for age-related macular degeneration: A meta-analysis.PLoS One2014910e10974410.1371/journal.pone.010974425330364
     [Google Scholar]
  113. KampougerisG. SpyropoulosD. MitropoulouA. Intraocular pressure rise after anti-vegf treatment: Prevalence, possible mechanisms and correlations.J. Curr. Glaucoma Pract.201371192410.5005/jp‑journals‑10008‑113226997776
     [Google Scholar]
  114. Ghasemi FalavarjaniK. NguyenQ.D. Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature.Eye (Lond.)201327778779410.1038/eye.2013.10723722722
     [Google Scholar]
  115. FintakD.R. ShahG.K. BlinderK.J. RegilloC.D. PollackJ. HeierJ.S. HollandsH. SharmaS. Incidence of endophthalmitis related to intravitreal injection of bevacizumab and ranibizumab.Retina200828101395139910.1097/IAE.0b013e3181884fd218827737
     [Google Scholar]
  116. IpMS DomalpallyA HopkinsJJ WongP EhrlichJS Long-term effects of ranibizumab on diabetic retinopathy severity and progression.Arch Ophthalmol2012130911455210.1001/archophthalmol.2012.1043
     [Google Scholar]
  117. Mezad-KourshD. GoldsteinM. HeilwailG. Zayit-SoudryS. LoewensteinA. BarakA. Clinical characteristics of endophthalmitis after an injection of intravitreal antivascular endothelial growth factor.Retina20103071051105710.1097/IAE.0b013e3181cd47ed20616683
     [Google Scholar]
  118. ArevaloJ.F. MaiaM. FlynnH.W.Jr SaraviaM. AveryR.L. WuL. FarahM.E. PieramiciD.J. BerrocalM.H. SanchezJ.G. Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy.Br. J. Ophthalmol.200892221321610.1136/bjo.2007.12714217965108
     [Google Scholar]
  119. GoodT.J. KimuraA.E. MandavaN. KahookM.Y. Sustained elevation of intraocular pressure after intravitreal injections of anti-VEGF agents.Br. J. Ophthalmol.20119581111111410.1136/bjo.2010.18072920702430
     [Google Scholar]
  120. TsengJ.J. VanceS.K. Della TorreK.E. MendoncaL.S. CooneyM.J. KlancnikJ.M. SorensonJ.A. FreundK.B. Sustained increased intraocular pressure related to intravitreal antivascular endothelial growth factor therapy for neovascular age-related macular degeneration.J. Glaucoma201221424124710.1097/IJG.0b013e31820d7d1921423038
     [Google Scholar]
  121. HoangQ.V. MendoncaL.S. Della TorreK.E. JungJ.J. TsuangA.J. FreundK.B. Effect on intraocular pressure in patients receiving unilateral intravitreal anti-vascular endothelial growth factor injections.Ophthalmology2012119232132610.1016/j.ophtha.2011.08.01122054994
     [Google Scholar]
  122. KaragiannisD.A. MitropoulosP. LadasI.D. Large subretinal haemorrhage following change from intravitreal bevacizumab to ranibizumab. Ophthalmologica Journal international d’ophtalmologie International journal of ophthalmology.Z. Augenheilkd.20092234279282
     [Google Scholar]
  123. HahnP. ChungM.M. FlynnH.W.Jr HuangS.S. KimJ.E. MahmoudT.H. SaddaS.R. DugelP.U. Postmarketing analysis of aflibercept-related sterile intraocular inflammation.JAMA Ophthalmol.2015133442142610.1001/jamaophthalmol.2014.565025590968
     [Google Scholar]
  124. FineH.F. RothD.B. ShahS.P. HaqueT. WheatleyH.M. Frequency and characteristics of intraocular inflammation after aflibercept injection.Retina201535468168610.1097/IAE.000000000000039825394166
     [Google Scholar]
  125. AmbatiJ. AmbatiB.K. YooS.H. IanchulevS. AdamisA.P. Age-related macular degeneration: Etiology, pathogenesis, and therapeutic strategies.Surv. Ophthalmol.200348325729310.1016/S0039‑6257(03)00030‑412745003
     [Google Scholar]
  126. LeungD.W. CachianesG. KuangW.J. GoeddelD.V. FerraraN. Vascular endothelial growth factor is a secreted angiogenic mitogen.Science198924649351306130910.1126/science.24799862479986
     [Google Scholar]
  127. SengerD.R. GalliS.J. DvorakA.M. PerruzziC.A. HarveyV.S. DvorakH.F. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid.Science1983219458798398510.1126/science.68235626823562
     [Google Scholar]
  128. Drugs. Medications for macular degeneration.Available from: https://www.drugs.com/condition/macular-degeneration.html
  129. FramptonJ.E. Ranibizumab.Drugs201272450952310.2165/11208410‑000000000‑0000022356289
     [Google Scholar]
  130. LangG.E. BertaA. EldemB.M. SimaderC. SharpD. HolzF.G. SutterF. GerstnerO. MitchellP. RESTORE Extension Study Group Two-year safety and efficacy of ranibizumab 0.5 mg in diabetic macular edema: interim analysis of the RESTORE extension study.Ophthalmology2013120102004201210.1016/j.ophtha.2013.02.01923725735
     [Google Scholar]
  131. RajendramR Fraser-BellS KainesA A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3.Arch Ophthalmol20121308972910.1001/archophthalmol.2012.39322491395
     [Google Scholar]
  132. LynchS.S. ChengC.M. Bevacizumab for neovascular ocular diseases.Ann. Pharmacother.200741461462510.1345/aph.1H31617355998
     [Google Scholar]
  133. Regeneron Pharmaceuticals Inc. REGENERON ANNOUNCES EYLEA® (AFLIBERCEPT) injection approved for the treatment of diabetic MACULAR EDEMA (DME) in JAPAN 2014.Available from: https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-eylear-aflibercept-injection-approved-0
  134. Bayer India. Bayer’s Aflibercept injection (EyleaTM) for intravitreal use receives DCGI Approval for Diabetic Macular Edema Indication.Available from: https://www.bayer.in/en/news/bayers-aflibercept-injection-eyleatm-for-intravitreal-use-receives-dcgi-approval-for-diabetic
  135. SchwartzS.G. ScottI.U. FlynnH.W.Jr StewartM.W. Drug delivery techniques for treating age-related macular degeneration.Expert Opin. Drug Deliv.2014111616810.1517/17425247.2013.85913524219407
     [Google Scholar]
  136. Drugs. Macugen prices.Available from: https://www.drugs.com/price-guide/macugen
  137. Drugs. Eylea prices.Available from: https://www.drugs.com/price-guide/eylea
  138. Drugs. Lucentis prices.Available from: https://www.drugs.com/price-guide/lucentis
  139. DedaniaV.S. BakriS.J. Current perspectives on ranibizumab.Clin. Ophthalmol.2015953354225848203
     [Google Scholar]
  140. RossE.L. HuttonD.W. SteinJ.D. BresslerN.M. JampolL.M. GlassmanA.R. Diabetic Retinopathy Clinical Research Network Cost-effectiveness of aflibercept, bevacizumab, and ranibizumab for diabetic macular edema treatment: Analysis from the diabetic retinopathy clinical research network comparative effectiveness trial.JAMA Ophthalmol.2016134888889610.1001/jamaophthalmol.2016.166927280850
     [Google Scholar]
/content/journals/cdr/10.2174/0115733998294968240405091023
Loading
Exploring the Therapeutic Potential of Anti-VEGF Drugs for the Management of Diabetic Retinopathy: An Overview
Curr. Diabetes Rev. 21, e160424228951 (2025); https://doi.org/10.2174/0115733998294968240405091023
/content/journals/cdr/10.2174/0115733998294968240405091023
/content/journals/cdr/10.2174/0115733998294968240405091023
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): aflibercept; anti-VEGF; bevacizumab; Diabetic retinopathy; pegaptanib; ranibizumab

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test